Background Diffuse large B-cell lymphoma (DLBCL) exhibits heterogeneous clinical outcomes, including variations in event-free survival (EFS). Tumor microenvironment (TME) components, particularly absolute monocyte count (AMC), tumor-associated macrophages (TAMs), and tumor-infiltrating lymphocytes (TILs) have been implicated in prognosis, although findings remain inconsistent. This study evaluates the prognostic value of AMC, TAMs (CD163), and TILs (CD8) on two-year EFS in DLBCL patients treated with R-CHOP. Methods A retrospective cohort study of 108 DLBCL patients treated from January 2014 to March 2021 was conducted. AMC was obtained from peripheral blood, while CD163 and CD8 expressions were analyzed via immunohistochemistry. Associations with two-year EFS were assessed using hazard ratios (HR), and correlations between AMC and tissue immune markers were evaluated. Results High AMC and CD163 expression were significantly associated with poorer two-year EFS (HR = 9.82 and 8.57; both p < 0.001), whereas elevated CD8 expression predicted better outcomes (HR = 0.13; p < 0.001). AMC positively correlated with CD163 (r = 0.577; p < 0.001) and negatively with CD8 (r = –0.599; p < 0.001). Conclusion AMC and CD163 are negative prognostic markers, while CD8 is protective. AMC may reflect the immune profile of the TME and serve as a practical prognostic biomarker in DLBCL.
Background Diffuse large B-cell lymphoma (DLBCL) exhibits heterogeneous clinical outcomes, including variations in event-free survival (EFS). Tumor microenvironment (TME) components, particularly absolute monocyte count (AMC), tumor-associated macrophages (TAMs), and tumor-infiltrating lymphocytes (TILs) have been implicated in prognosis, although findings remain inconsistent. This study evaluates the prognostic value of AMC, TAMs (CD163), and TILs (CD8) on two-year EFS in DLBCL patients treated with R-CHOP. Methods A retrospective cohort study of 108 DLBCL patients treated from January 2014 to March 2021 was conducted. AMC was obtained from peripheral blood, while CD163 and CD8 expressions were analyzed via immunohistochemistry. Associations with two-year EFS were assessed using hazard ratios (HR), and correlations between AMC and tissue immune markers were evaluated. Results High AMC and CD163 expression were significantly associated with poorer two-year EFS (HR = 9.82 and 8.57; both p < 0.001), whereas elevated CD8 expression predicted better outcomes (HR = 0.13; p < 0.001). AMC positively correlated with CD163 (r = 0.577; p < 0.001) and negatively with CD8 (r = –0.599; p < 0.001). Conclusion AMC and CD163 are negative prognostic markers, while CD8 is protective. AMC may reflect the immune profile of the TME and serve as a practical prognostic biomarker in DLBCL.
Platelet transfusion refractoriness (PTR) is a conditioikb1n where platelet counts fail to increase adequately in several transfusions, often found in hemato-oncological situations. PTR poses life-threatening risks to patients, especially in cases when the platelet is very low, and transfusion is life-saving. It can be differentiated into immune or non-immune causes. While non-immune causes predominate, immune factors, particularly anti-HLA antibodies, are also notable in many cases. Accurately determining if platelet transfusion failure originates from an immune or non-immune cause is vital due to differing treatments, particularly the need for HLA-compatible platelets with immune causes. Yet, a lack of consensus exists regarding the diagnostic methods and treatment modalities. Therefore, this review aims to explore the origins, mechanisms, diagnostic criteria, and management approaches concerning PTR.
We present a case of a 38-year-old person living with HIV (PLHIV) diagnosed with refractory idiopathic hypereosinophilic syndrome (HES). His initial symptoms were pruritic skin rash, dry cough, and diarrhea. The patient was unresponsive to corticosteroid as a first-line therapy. Subsequent treatment with Imatinib mesylate 100 mg per day resulted in excellent and sustained hematological and clinical response, with a likely molecular response as well.
The interplay between JAK2 mutation, thrombosis, and the baseline clinical and hematologic profile of MPN remains poorly understood. This study aims to provide insight on the relationship between the clinical profile and hematologic findings, JAK2 V617F mutation, and the occurrence of thrombotic events in BCR-ABL1 negative MPNs. We retrospectively analyzed 198 patients with BCR-ABL1-negative MPNs to assess associations between JAK2 V617F mutation status, hematologic parameters, clinical features, and thrombotic events. Patients under 40 years old were associated with JAK2 V617F-negative MPN (p<0.05). In PV patients, cardiovascular comorbidities were associated with a 4.5-fold increased risk of thrombosis (OR 4.59; CI 1.57-13.43; p=0.005). Mutated-JAK2 V617F MPN was associated with lower platelets and higher WBC count, while thrombosis was associated with higher hemoglobin and hematocrit (p<0.01). However, we found no associations between JAK2 V617F mutation and thrombotic events across all MPN subtypes. Cardiovascular comorbidity are an independent risk factor for thrombosis in PV. While JAK2 V617F mutation was associated with distinct hematologic profiles, it was not independently linked to thrombotic risk. These findings highlight the significance of clinical comorbidities and hematologic parameters in thrombotic event occurrences in MPN patients.
1 March 2023 in Electronic Journal of General Medicine
Background: In the era of coronavirus disease 2019 (COVID-19), it is mandatory to identify vulnerable people with cancers as they have impaired immune system that can lead to high mortality. This study analyzes the complete blood count (CBC) derived inflammatory biomarkers and the level of anti-SARS-CoV-2 neutralizing antibody (NAb) and spike protein’s receptor-binding domain immunoglobulin G (S-RBD IgG) among cancer survivors. Methods: A cross-sectional study was conducted in patients with either solid or hematological cancers who had received two-doses of COVID-19 vaccinations within six months. Results: From 119 subjects, the COVID-19 vaccines demonstrated laboratory efficacy (median NAb=129.03 AU/mL; median S-RBD IgG=270.53 AU/mL). The seropositive conversion of NAb reached 94.1% and S-RBD IgG reached 93.3%. Additionally, the S-RBD IgG had very weak correlation with absolute monocyte count (R=-0.185; p-value=0.044). The NAb also had very weak correlation with leukocyte (Kendall’s tau-b (τb)=-0.147; p-value=0.019), absolute neutrophil count (τb=-0.126; p-value=0.044), absolute eosinophil count (τb=-0.132; p-value=0.034). Conclusion: The seropositivity rate of anti-SARS-CoV-2 NAb and S-RBD IgG were significantly high. However, the CBC derived inflammatory biomarkers had poor correlation with anti-SARS-CoV-2 NAb and S-RBD IgG. Thus, anti-SARS-CoV-2 NAb and S-RBD IgG are currently the only reliable markers for measuring the COVID-19 vaccine efficacy which should be widely accessible.